Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance. by Hufnagel, Antonia et al.















Maternal but not fetoplacental health can be improved by
metformin in a murine diet-induced model of maternal
obesity and glucose intolerance
Antonia Hufnagel1 , Denise S. Fernandez-Twinn1 , Heather L. Blackmore1, Thomas J. Ashmore1,
Robert A. Heaton2 , Benjamin Jenkins1, Albert Koulman1, Iain P. Hargreaves2, Catherine E. Aiken3,4
and Susan E. Ozanne1
1Wellcome Trust-MRC Institute of Metabolic Science, Level 4, Addenbrooke’s Hospital, University of Cambridge Metabolic Research Laboratories and
MRC Metabolic Diseases Unit, Cambridge, UK
2School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK
3Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, UK
4National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
Edited by: Laura Bennet & Janna Morrison
The peer review history is available in the Supporting Information section of this article
(https://doi.org/10.1113/JP281902#support-information-section).
A. Hufnagel and D. S. Fernandez-Twinn contributed equally to this work. S. E. Ozanne is senior author.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society DOI: 10.1113/JP281902
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
2 A. Hufnagel and others J Physiol 0.0
Abstract Maternal obesity is a global problem that increases the risk of short- and long-term
adverse outcomes for mother and child, many of which are linked to gestational diabetes mellitus.
Effective treatments are essential to prevent the transmission of poor metabolic health frommother
to child.Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes
mellitus; however, its wider effects on maternal and fetal health are poorly explored. In this study we
used amouse (C57Bl6/J) model of diet-induced (high sugar/high fat) maternal obesity to explore the
impact of metformin on maternal and feto-placental health. Metformin (300 mg kg−1 day−1) was
given to obese females via the diet and was shown to achieve clinically relevant concentrations in
maternal serum (1669 ± 568 nM in late pregnancy). Obese dams developed glucose intolerance
during pregnancy and had reduced uterine artery compliance. Metformin treatment of obese
dams improved maternal glucose tolerance, reduced maternal fat mass and restored uterine artery
function. Placental efficiency was reduced in obese dams, with increased calcification and reduced
labyrinthine area. Consequently, fetuses from obese dams weighed less (P < 0.001) at the end
of gestation. Despite normalisation of maternal parameters, metformin did not correct placental
structure or fetal growth restriction. Metformin levels were substantial in the placenta and fetal
circulation (109.7 ± 125.4 nmol g−1 in the placenta and 2063 ± 2327 nM in fetal plasma). These
findings reveal the distinct effects of metformin administration during pregnancy on mother and
fetus and highlight the complex balance of risk vs. benefits that are weighed in obstetric medical
treatments.
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Abstract figure legendObesogenic diet during pregnancy leads to impairedmetabolic health in themother and reduced
fetal growth and placental pathologies. Maternal metabolic health can be markedly improved by metformin treatment;
however, this is not the case for fetal and placental health andmetformin reaches the placenta and fetal circulation, which
could have direct short- and long-term effects.
Key points
 Maternal obesity and gestational diabetes mellitus have detrimental short- and long-term effects
for mother and child.
 Metformin is commonly used to treat gestational diabetes mellitus in many populations
worldwide but the effects on fetus and placenta are unknown.
 In a mouse model of diet-induced obesity and glucose intolerance in pregnancy we show reduced
uterine artery compliance, placental structural changes and reduced fetal growth.
 Metformin treatment improved maternal metabolic health and uterine artery compliance but did
not rescue obesity-induced changes in the fetus or placenta. Metformin crossed the placenta into
the fetal circulation and entered fetal tissue.
 Metformin has beneficial effects on maternal health beyond glycaemic control. However, despite
improvements in maternal physiology, metformin did not prevent fetal growth restriction or
placental ageing. The high uptake of metformin into the placental and fetal circulation highlights
the potential for direct immediate effects of metformin on the fetus with possible long-term
consequences postnatally.
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Introduction
The growing prevalence of obesity worldwide means that
inmany populations at least 50%ofwomen are overweight
or obese at the start of pregnancy (Hill et al. 2019). Obesity
during pregnancy is associated with increased risk of
complications, including preeclampsia, preterm delivery,
stillbirth, and importantly gestational diabetes mellitus
(GDM) (Stephenson et al. 2018). It is now estimated that
the prevalence of GDM ranges from 1% to 30%worldwide
(Mcintyre et al. 2019).
Maternal obesity and untreated GDM during
pregnancy have direct effects on the fetus, with
implications for long-term offspring health (Alfaradhi &
Ozanne, 2011). Observational studies in humans show
increased risks of obesity (Hu et al. 2019), type 2 diabetes
(Lahti-Pulkkinen et al. 2019) and cardiovascular disease
(Gaillard, 2015) in offspring born to obese mothers
and those with GDM (Mitanchez et al. 2015). Studies
in animal models by our laboratory and others have
shown previously that these relationships are causal.
These studies demonstrate that obesity and/or glucose
intolerance during pregnancy lead to cardiac dysfunction
(Blackmore et al. 2014), insulin resistance (Isganaitis et al.
2014), hyperphagia (Steculorum & Bouret, 2011), obesity
(Samuelsson et al. 2008) and fatty liver (Alfaradhi et al.
2014) in young adult offspring. However, the mechanisms
linking fetal development and growth in affected pre-
gnancies with long-term adverse effects are complex and
yet to be fully understood.
The placenta is the key interface between the mother
and fetus, and therefore a likely mediator of the effects
of maternal health on the developing fetus. Studies in
humans and in animal models have shown that placentas
from obese pregnancies display lipotoxicity (Jarvie et al.
2010) and inflammation (Pantham et al. 2015), and have
reduced placental vessel density (Hayes et al. 2012),
highlighting that the protective capacities of the placenta
can be exhausted in diabetic and/or obese pregnancies
(Desoye &Wells, 2021).
Interventions need to be carefully assessed to improve
maternal and fetal health. Lifestyle and dietary inter-
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ventions are generally the first recommendation to treat
GDM, and are successful in >50% of women (American
Diabetes Association, 2019). If these interventions fail,
pharmacological interventions such as metformin,
glyburide, or insulin are implemented (Society for
Maternal-Fetal Medicine, 2018). Metformin, a biguanide
with glucose-lowering actions, is a pragmatic alternative
to insulin as it can be taken orally, does not need to be
refrigerated, and does not cause hypoglycaemic episodes
(Gray et al. 2017). In the UK, National Institute for Health
and Care Excellence (NICE) guidelines recommend
metformin as a first-line drug therapy for GDM (NICE,
2015) whereas other countries, such as Germany and
Turkey (Schäfer-Graf et al. 2018; Society of Endocrinology
andMetabolism of Turkey, 2019), aremuchmore cautious
regarding metformin use in pregnancy.
It is well-established that metformin treatment of
GDM improves glycaemic control in the mother and is
associatedwith reduced gestational weight gain (Syngelaki
et al. 2016). However, there is relatively little data
regarding immediate or long-term effects of maternal
metformin use on the offspring (Tarry-Adkins et al. 2019).
Unlike insulin, metformin freely crosses the placenta
and reaches circulating concentrations in the fetus that
match those in the mother (Priya & Kalra, 2018).
Human studies looking at polycystic ovary syndrome,
GDM and type 2 diabetes pregnancies suggest that intra-
uterine metformin exposure leads to reduced birthweight
followed by increased adiposity later in childhood (Rowan
et al. 2011; Guro et al. 2018; Feig et al. 2020). However,
data on immediate effects of metformin on the fetus
and placental function are scarce (Tarry-Adkins et al.
2019) despite the possibility that metformin could have
potential negative effects on the placenta and fetal
development due to its inhibition of the mTOR pathway,
cell proliferation and mitochondrial function (Lindsay &
Loeken, 2017).
We addressed this knowledge gap by characterising
maternal metabolic health, fetal growth and placental
structure and function using a murine model of
metformin treatment for diet-induced obesity and glucose
intolerance in pregnancy.
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Methods
Ethical approval
Animal studies were carried out following review and
approval by the University of Cambridge Animal Welfare
Ethical Review Body and in accordance with the UK
Animals Scientific Procedures Act 1986. The study was
performed under the animal project licence P5FDF0206
issued by the UK Home Office and complies with the
standards stated for The Journal of Physiology (Grundy,
2015).
Animal work
A model of maternal diet-induced obesity that is well
established in our laboratory and is described in detail
elsewhere (Fernandez-Twinn et al. 2012) was used. Mice
were purchased from Charles River Laboratories (Cat. no.
000664, RRID: IMSR_JAX:000664) and bred in house.
For all measurements (other than intraperitoneal glucose
tolerance tests (ipGTT)) 14 control, 14 obese and 13
obese metformin-treated animals were included. For
ipGTT, power calculations demonstrated that a greater
n was required, and hence 20 control, 20 obese and
19 obese metformin-treated animals were used for this
measurement.
After weaning at 3 weeks of age, female C57Bl6/J mice
were fed ad libitum either an obesogenic diet high in
sugar and fat (10% simple sugars, 20% animal fat, 23%
protein (w/w), 4.5 kcal g−1, Special Dietary Services, Cat.
no. 824053) together with condensed milk in glass pots
(55% simple sugar, 8% fat, 8% protein (w/w), 3.2 kcal g−1,
Nestle, Cat. no. 12029969) and a mineral mix (MP
Biomedicals, Cat. no. AIN93G) or a control chow diet
(RM1, 7% simple sugars, 3% fat, 15% protein (w/w),
3.5 kcal g−1, Special Dietary Services, Cat. no. 801002). In
this model there is no difference in protein intake between
the groups as shown previously (Samuelsson et al. 2008;
Maragkoudaki et al. 2020). Assignment of dietary groups
was carried out by an animal technician who was not
involved in any of the subsequent physiological or
molecular analyses. Mice were then mated for a first
pregnancy at 6 weeks of age after which they were allowed
at least 1 week of rest for recovery. Animals on a control
diet with a body weight ≤ 25 g were mated for the second
experimental pregnancy.Mice fed an obesogenic diet were
mated or dosed with metformin once they reached a body
weight of ≥ 35 g. For all groups this was at approximately
18 weeks of age. Mice were single-housed and kept in
individually ventilated cages with wood chip bedding,
free access to food, water and environmental enrichment
(nesting material and a tunnel) in a 12 h light/dark cycle.
Metformin (MP Biomedicals Cat. no. 02151691-CF)
was administered 1 week prior to mating and throughout
pregnancy in the condensedmilk.Weighing of condensed
milk twice a week allowed the calculation and adjustment
ofmetformin intake (inmg kg−1 day−1). The average dose
that animals received was 255.2 ± 48.0 mg kg−1 day−1,
which lies in the desired range of 200–300mg kg−1 day−1,
based on clinically relevant doses (Salomäki et al. 2013).
Liquid chromatography-mass spectrometry (LC-MS)
showed the mean serum metformin concentration was
1669 ± 568 nM, which falls within the clinical range
reported in human pregnancies (Liao et al. 2020). The
study was designed to address whether intervention with
metformin can improve detrimental effects of a pregnancy
complicated by obesity and GDM, and therefore no
metformin-treated control group was used. As metformin
is not given to lean pregnant women this is not clinically
relevant. This is in line with the ARRIVE guidelines
(NC3Rs) so that the minimal number of animals needed
is used.
Intraperitoneal glucose tolerance test (ipGTT)
Dams were fasted for 4 h on the morning of embryonic
day E17.5. Glucose (1 mg kg−1) was injected intra-
peritoneally, and blood glucose levels measured at 0, 15,
30, 60 and 120 min using a glucometer (AlphaTRAK,
Abbot Logistics). Collection of tail blood was performed
at 0 min into capillary tubes (Hirschmann-Laborgeräte).
Glucose curves are shown as a percentage of starting
glucose. If the glucose levels rose less than 50% between
fasting and time points 15 and or 30 min the GTT data
was excluded. Insulin was measured with the Crystal
Chem Mouse Insulin ELISA (Ultra-Sensitive) kit (Cat.
no. 90080). The HOMA-IR was calculated according to
the following formula: fasting insulin (mU l−1) × fasting
glucose (mmol l−1)/22.5.
Fat mass assessment
Fat mass at E18.5 was assessed via time domain nuclear
magnetic resonance (TD-NMR, Bruker) measurements.
Ultrasound assessments
Uterine, umbilical and fetal middle cerebral artery
function were assessed via ultrasound in the morning
of day E18.5 (FUJIFILM VisualSonics, Vevo3100).
Anaesthesia in the dams was induced with inhalation
of 2% isoflurane and then maintained at 1.5% isoflurane.
Isoflurane is commonly used in ultrasound as it affects
heart and respiration rate the least compared to other
anaesthetics (Janssen et al. 2004). Mice were placed on
a heated platform, the electrocardiogram monitored,
and body temperature measured via a rectal probe and
kept at around 36°C throughout. Uterine artery Doppler
measurements were obtained by using the bladder and
the split of the uterine and iliac artery from the abdominal
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aorta as landmarks (Zhang & Croy, 2009). The pulsatility
and resistance index of the uterine artery were corrected
for maternal heart rate (Ochi et al. 2003). Both indices are
a surrogate measure for the vessel resistance and vascular
compliance (Holmgren et al. 2020). The fetal middle
cerebral artery (MCA) was scanned in a cross-sectional
view of the head at the level of the circle of Willis and
the umbilical artery was measured in a free loop trans-
verse section (Hernandez-Andrade et al. 2014). The
cerebroplacental ratio (CPR) was calculated via dividing
the pulsatility index of the MCA by that of the umbilical
artery. Scanned fetuses were marked on the skin of the
dam so that they could be identified and sexed upon
dissection. The placental pulsatility index (PPI) was
calculated using the following formula: PPI = (uterine
artery PI + umbilical artery PI)/2 (Gudmundsson
et al. 2017). Analysis of the ultrasound recordings was
performed with the VevoLab software.
Dissections
After the ultrasound measurements were taken, cardiac
puncture was performed under 2% isoflurane anaesthesia
and death confirmed by cervical dislocation. Tissues of the
dams were collected, and fetuses and placentas dissected
out. Fetuses were killed by immersion in cold PBS. Fetal
weight was recorded, and biometry measured with a
calliper. Amniotic fluidwas taken from the intact amniotic
sac via a syringe. Fetal blood was obtained by collecting
the blood after decapitation into capillary tubes. Fetal liver
and kidneys were dissected out, quickly frozen on dry
ice and stored at −80°C. Fetuses were sexed visually by
detection of a black spot between tail and genital tubercle
present in male fetuses (Deeney et al. 2016) and sub-
sequently confirmed via molecular analysis based on a
protocol from McFarlane et al. (2013). Briefly, genomic
DNAwas isolated, and PCR performed (GO Taq G2DNA
polymerase from Promega, Cat. no. PAM7841, annealing
temperature 57°C) with the following primer: SX_F,
5’-GATGATTTGAGTGGAAATGTGAGGTA-3’; SX_R,
5’-CTTATGTTTATAGGCATG CACCATGTA-3’. On an
agarose gel, male samples display one band at 280 bp,
female samples show 2–3 bands (480 bp, 660 bp, 685 bp).
sFlt measurement
sFlt (VEGF-R1) was measured in maternal serum by
ELISA according to themanufacturer’s instructions (R&D
Systems, Cat. no. MVR100).
Histology (liver and placenta)
Dam livers and placentas were immersion-fixed in
10% formalin and processed. Dam liver sections (one
mid-section, 5 μM) were stained with Haematoxylin
and Eosin and fat vacuole content quantified with the
HALO software (Indica labs). Artificial intelligence of
the software was used to exclude vessels for the sub-
sequent analysis of the fat vacuoles, via the HALO vacuole
quantification module.
Placental sections (one mid-section, 5 μM) were
deparaffinised and rehydrated and incubated in water for
15 min at 60°C. Antigen retrieval was performed (97°C,
pH = 9, 20 min, Vector, Cat. no. H-3301) and the slides
blocked with 1× animal-free blocking solution for 1 h
(Vector, Cat. no. SP-5030). Slides were incubated with
the primary antibodies for CD31 and Tpbpa (R&D, Cat.
no. AF3628, RRID: AB_2161028 1:40 dilution and abcam,
Cat. no. ab104401, RRID: AB_10901888, 1:1000 dilution
in antibody diluent (Vector, Cat. no. SP-5035)) overnight
at 4°C. After washing (0.5% Tween in TBS, T-TBS) the
secondary antibodies were applied subsequently for 1 h
at room temperature (first NL557 (R&D, Cat. no. NL001,
RRID: AB_663766) at 1:200, then Alexa488 (Invitrogen,
Cat. no. A11008, RRID: AB_143165) at 1:1000). After
washes in T-TBS and PBS slides were stained with DAPI
for 10 min in the dark and TrueVIEW quenching solution
(Vector, SP-4800) was subsequently used according to the
protocol. Slides were mounted in Vectashield hard set
anti-fade mounting medium (Vector, Cat. no. H-1400).
Analysis of the slides was performed blind with HALO
software by manually delineating the placental layers.
To analyse placental calcification, Alizarin Red staining
was performed (Orchard, 2013). Sections were dewaxed
and immediately put into 95% alcohol, slides were
air-dried and incubated in Alizarin Red (Sigma-Aldrich,
Cat. no. A-5533) solution for 5 min (1% aqueous solution
pH = 6.4, ammonium hydroxide). After rinsing under
water, slides were counterstained with Fast Green (0.05%
FCF (Sigma-Aldrich, Cat. no. F-7252) in 0.2% acetic acid
for 15 s). Slides were washed under water, dehydrated,
cleared and mounted in synthetic resin. Slides were
analysed automatically via the HALO software with a
classifier programmed to count Alizarin Red positive
and negative areas within the manually delineated whole
placental section.
Quantitative RT-PCR
RNA from placentas, fetal livers and kidneys (5 mg) was
extracted with a miRNeasy Micro kit (Qiagen, Cat. no.
217084), 1 fetus per sex and litter with an n of 3 was used.
Fetal liver and kidneywere chosen as twometabolic tissues
that can be clearly dissected out in the E18.5 fetus. DNA
was digested on columnwith a DNaseQiagen set (Qiagen,
Cat. no. 79254). RNA concentrations were measured with
the Nanodrop and concentrations were between 300 and
700 ngμl−1 for all samples with a A260/280 ratio between
2 and 2.15. RNA was heated at 65°C prior to reverse
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Slc22a4 NM_019687.3 Mm00457739 73 bp
Slc47a1 NM_026183.5 Mm00840361 80 bp
Slc29a4 NM_146257.2 Mm00525575 82 bp
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NM_023281.1 Mm01352366 82 bp
transcription. Reverse transcription was performed with
1 μg total RNA in a 20 μl reaction with the RevertAid kit
(Thermo Scientific, Cat. no. K1691) using the following
protocol: 5 min at 25°C, 60 min at 42°C and 5 min at
70°C. QPCRwas performed with the TaqManMaster Mix
(Thermo Scientific, Cat. no. 4304437) in a 7 μl reaction
using a dilution of 1:16 of the RT reaction mix. All
TaqMan probes were purchased from Thermo Scientific
and are listed in Table 1. The qPCR was performed on a
QuantStudio 7 Flex Real-Time PCR system for 384 wells
using the following cycling conditions: 2 min at 50°C,
10 min at 95°C and then 15 s at 95°C and 1 min at 60°C
for 40 cycles. The MIQE guidelines were followed for the
quantitative RT-PCR (Bustin et al. 2009).
Liquid chromatography-mass spectrometry (LC-MS)
Metformin and metformin-d6 were purchased from
Sigma Aldrich (Cat. no. PHR1084) and QMX laboratories
(Cat. no. D-6012) and all solvents/additives were at
least HPLC grade. Metformin was extracted as pre-
viously described (Jenkins et al. 2020). Briefly, the samples
were weighed/pipetted into plastic tubes (Eppendorf)
with a 5 mm stainless steel ball. Then, 400 μl of
chloroform:methanol (2:1, Sigma Aldrich, Cat. no. 34854
and Cat. no. M/4056/17) solution was added. The samples
were then homogenised using a Bioprep-24-1004 homo-
geniser (Allsheng) run at 4.5 m s−1 for 60 s. A 100 μl
aliquot of the metformin-d6 (1 μM in water) was
added followed by the addition of 600 μl of chloroform:
methanol (2:1) solution and 300 μl of water (Sigma
Aldrich, Cat. no. 1.15333). The samples were vortexed
and centrifuged at ∼21,000 g for 5 min. The aqueous
extracts were transferred into glass vials and dried down
using a Concentrator Plus (Eppendorf) run at 60°C for
180 min. The samples were reconstituted in 100 μl of
chromatography starting conditions and transferred into
glass vial inserts for analysis. LC-MS analysis was achieved
using a HPLC System (Shimadzu UK Limited) injecting
5 μl of the sample onto a Scherzo SM-C18 column
(150 mm × 3 mm I.D., 3 μM) maintained at 40°C.
Mobile phase [A] was 30 mM ammonium acetate (Sigma
Aldrich, Cat. no. 17836) in water with 0.02% acetic acid
(Sigma Aldrich, Cat. no. 222142500). Mobile phase [B]
was 20% acetonitrile (SigmaAldrich, Cat. no. 34851), 80%
water with 0.8% acetic acid. The flow was maintained at
0.5 ml min−1 with the following gradient: 0.00 min_10%
[B]; 0.20 min_10% [B]; 1.20 min_99% [B]; 5.00 min_99%
[B]; 5.10 min_10% [B]; 8.00 min_10% [B]. The needle
was washed using 50:50 water:acetonitrile solution. An
Exactive Orbitrap with a heated electrospray ionisation
source (Thermo Fisher Scientific) was calibrated before
sample analysis. The instrument tune file (positive mode,
full-scan:m/z 100 to 200, resolution: 2 Hz) was optimised
for metformin and applied throughout the analysis.
Statistical analyses
The visual difference in body weight of control and
obese dams means that it is not possible to blind the
individual carrying out the physiological analysis to
maternal group. However histological analysis was
performed following coding and blinding of the sample
group to the individual carrying out the analysis. One-
and two-way ANOVA, Pearson correlation and Student’s
paired t test were performed with the GraphPad Prism
9.0.0 Software, statistical outliers were removed following
Rout testing, and n numbers are indicated below each
figure and mean ± SD presented in the text and the
figures. Assumptions for the use of parametric tests
were tested via the Shapiro-Wilk test for normality
and the Brown-Forsythe test for equal variance. The
fasting insulin, ipGTT AUC, HOMA-IR and liver
steatosis data showed unequal variance and therefore
a Welch ANOVA was performed. All other data met the
assumptions required. The heatmap, organisation of the
data, calculations and linear models were performed in
R Studio (Version 1.3.959). Random-effects models were
constructed for the fetal data (using the lmer4 package in
R) to account for litter structure as a random effect, with
sex and the experimental group as fixed effects. Other
possible co-variates, for example litter size and position
within the uterus, did not significantly improve the fit of
the model and were therefore not included in the final
model for analysis. The model was used for the analysis of
the fetal bodyweight, fetal biometrical measurements, the
placental weight and the body weight to placental ratio
allowing all fetuses in a litter to be included in the analysis.
However, for visualisation the mean ± SD is presented.
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For the analysis of the fetal liver weight, the placental
structure (placental labyrinth and calcium), the umbilical
artery pulsatility index, the PPI, the litter size, the MCA
and CPR one fetus per litter and sex was analysed and
analysis was performed with a two-way ANOVA with
maternal environment and fetal sex as the independent
variables. Whenever a subset of these animals was used
for a measure the n numbers are indicated in the figure
legend or in the text if a figure is not shown.
Results
Equal concentrations of metformin are found in the
maternal circulation and fetal circulation
Metformin concentrations in maternal serum
(1.67 ± 2.05 nmol ml−1) on E18.5 of pregnancy were
comparable to those previously reported in pregnant
women being treated for GDM (Liao et al. 2020).
Furthermore, comparable concentrations were pre-
sent in fetal plasma (2.06 ± 2.33 nmol ml−1, n = 13)
and the placenta (109.7 ± 125.4 nmol g−1, n = 13)
on E18.5 of pregnancy. There was therefore a strong
positive correlation betweenmaternal serum, fetal plasma
and placental metformin concentrations at this time
point (Fig. 1A and B). Metformin was also detected at
high levels in E13.5 placenta (143.8 ± 118.2 nmol g−1,
n = 4). Consistent with the uptake of metformin into
placental tissue, high levels of expression of 5 of the
11 known metformin transporters (Slc22a3, Slc22a4,
Slc22a5, Slc6a2, and Slc6a4) were detected in the placenta
at E18.5 (Fig. 1C). Of these Slc22a3 (Oct3), Slc6a2
(Net), Slc6a4 (Sert) were expressed at a higher level
than Slc22a5 (Octn2) and Slc22a4 (Octn1) (Fig. 1C).
Additional evidence for metformin passing into fetal
circulation was demonstrated by its detection in fetal
liver and also at significantly higher levels in fetal kidneys
(Fig. 1D, P = 0.02 for kidney vs. liver comparison via
Mann-Whitney test). Accordingly, seven transporters
were present in the fetal kidneys: Slc22a2 (Oct2), Slc22a3
(Oct3), Slc22a5 (Octn2), Slc6a4 (Sert), Slc47a1 (Mate1),
and Slc22a1 (Oct1) (Fig. 1C). In the liver only three trans-
porters (Slc22a4 (Octn1), Slc47a1 (Mate1), Slc6a4 (Sert))
were detected (Fig. 1C). Consistent with the highest
observed levels of metforminand metformin transporters
being observed in the fetal kidneys, and consistent with
its excretion in urine, metformin was also detected in the
amniotic fluid (Fig. 1D).
Metformin treatment in obese dams reduces fat mass
at the end of pregnancy
Dams randomised to the obesogenic diet were heavier
throughout pregnancy compared to those randomised to
control diet (Fig. 2A). At the end of gestation (E18.5),
obese untreated dams had a significantly higher fat mass
than the controls (P < 0.0001, Fig. 2B). Supplementing
the obese diet with metformin resulted in a significantly
lower fat mass in the obese metformin-treated group
compared to the obese untreated group at E18.5 (P= 0.02,
Fig. 2B).
Metformin supplementation in obese dams improves
glucose tolerance and liver steatosis
Glucose levels after a 4-h fast were not significantly
different between the three groups (8.9 ± 1.4 mmol l−1
in the control, 9.0 ± 1.9 mmol l−1 in the obese untreated
and 10.0 ± 2.1 mmol l−1 in the obese metformin-treated
group, P = 0.1 one-way ANOVA). However, glucose
tolerance at E17.5 (Fig. 2C) was impaired in the obese
untreated dams compared to the controls (area under
the curve (AUC): 526 ± 274 in obese untreated vs.
332 ± 108 in controls, P = 0.02, n = 20 and 20, inset in
Fig. 2C). Metformin treatment reduced the AUC of the
obese dams (AUC: 380± 189 in obese metformin-treated
n = 19), such that it was not different to the controls
(P = 0.7). Fasting insulin levels were increased in the
obese untreated dams compared to controls (P = 0.008,
Fig. 2D), and were reduced with metformin treatment but
they were still significantly increased compared to control
dams (P = 0.01, Fig. 2D). HOMA-IR was increased in the
obese group compared to controls (6.97 ± 1.67 in control
and 16.84 ± 11.13 in obese untreated dams, P = 0.01)
and remained increased compared to the controls after
metformin treatment (14.78 ± 9.22 in metformin-treated
dams, P = 0.03). In addition to impaired glucose
tolerance and insulin resistance, obese untreated dams
displayed increased liver fat compared to control dams
(P < 0.0001). This was reduced by metformin treatment
(P = 0.01 vs. obese untreated group) but remained
increased compared to controls (P < 0.001), Fig. 2E and
F). Overall, metformin treatment in pregnancy resulted
in improved metabolic health of the obese pregnant
females.
Metformin treatment in obese dams improves uterine
artery compliance and reduces serum sFlt levels
Doppler ultrasound analysis of the uterine artery blood
flow showed an increased pulsatility index (P = 0.003)
and increased resistance index (P = 0.005) in the obese
untreated dams compared to controls (Fig. 2G and H).
The increased indices are indicative of high resistance in
the vessel leading to impaired uterine artery blood flow.
The increased uterine artery resistance in obese dams
was rescued by metformin treatment. Both pulsatility and
resistance index (P= 0.04 and P= 0.03, respectively) were
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Sample type (E18.5) metformin(mean SD)









fetal liver 17.9 21.57 nmol/g
placenta 109.7 125.4 nmol/g
amnioticfluid 21.89 28.22 nmol/ml
Maternal serum 1.67 2.05 nmol/ml





















































Figure 1. Metformin given to the obese dam during pregnancy can reach the fetal circulation and fetal
tissues
A and B, metformin concentrations measured in maternal serum (A) and the placenta (B) were correlated with
fetal plasma concentrations (circles represent female, triangles represent male fetuses). Linear regression and
Pearson correlation coefficient r are shown. C, expression of eleven transporters (known for their ability to transport
metformin) was analysed in E18.5 placenta, fetal liver and fetal kidney (n = 3 per tissue type and sex respectively).
Raw CT values are shown, ranging from high expression (low CT values, red colour) to low expression (high CT
values, blue colour). Sdha was included as an endogenous control. D, metformin was measured in fetal kidney,
liver, amniotic fluid (n = 3 female and n = 3 male) and placentas (n = 7 male, n = 6 female) via LC-MS. Fluid samples
are expressed in nmol ml−1 and tissue samples in nmol g−1 to allow an approximate comparison.
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significantly reduced in obese metformin-treated dams
compared to obese untreated dams and were no longer
different to controls (P = 0.5 and P = 0.7, respectively,
Fig. 2G and H). Maternal fasting insulin levels correlated
positively with the uterine artery pulsatility index (Fig. 2I).
Serum sFlt levels (soluble VEGFR-1) were increased
significantly in the obese untreated group compared to
control dams (37.3 ± 12.2 ng ml−1 in obese untreated
vs. 26.2 ± 10.5 ng ml−1 in controls, P = 0.04, n = 13
and 14). Metformin treatment of obese dams reduced sFlt
levels (29.5± 10.7 ng ml−1, n= 12) to levels that were not
significantly different to controls (P = 0.7).
Figure 2. Maternal characteristics
A, body weight of the dams was measured on the day of the plug (E0.5), and on days 4.5, 6.5, 13.5 and 18.5 of
gestation (n = 14 for control, n = 14 for obese, n = 13 for metformin dams; means ± SD). Mixed model analysis is
shown. B, on day 18.5 fat mass was measured via TD-NMR (n = 5 for control, n = 9 for obese, n = 7 for metformin
dams). C, an ipGTT was performed after a 4-h fast on day 17.5 of pregnancy and glucose levels were measured
and presented as the difference from the starting glucose level (n = 20 for control, n = 20 for obese, n = 19 for
metformin dams; means ± SD, Welch ANOVA). The inset figure shows the area under the curve. D, fasting insulin
levels were measured (n = 13 for control, n = 14 for obese, n = 13 for metformin dams; mean ± SD, Welch
ANOVA). E, liver sections were stained with Haematoxylin and Eosin (representative images shown). F, the fat
vacuole content quantified with HALO image analysis platform as a percentage of the whole liver section (n = 14
for control, n = 13 for obese, n = 14 for metformin dams). G and H, pulsatility (G) and resistance (H) indices
were calculated and corrected for individual maternal heart rates (n = 12 for all three groups). I, fasting insulin
levels were correlated with uterine artery pulsatility index; linear correlation and Pearson correlation coefficient r
are shown. If not indicated differently statistical analyses in the figure used one-way ANOVA followed by Tukey’s
multiple comparison test; error bars show mean ± SD.
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Fetuses from obese dams with and without
metformin treatment are both symmetrically smaller
than controls
Male and female fetuses from obese dams with and
without metformin treatment weighed less compared
to controls (P < 0.001, Fig. 3A). Litter size was not
significantly different between groups (7.9 ± 1.6 fetuses
in the control, 8.4 ± 1.7 fetuses in the obese untreated
and 8.6 ± 1.2 fetuses in the obese metformin-treated
group; P = 0.5, one-way ANOVA). The reduction in fetal
weight was a result of symmetric growth restriction, with
reductions of similar magnitudes in crown-rump-length,
biparietal diameter, head length, abdominal transverse
diameter, and fetal liver weight (Fig. 3B–G). As expected,
indices of growth were significantly lower in female
fetuses compared to male fetuses (P < 0.05). There
were no significant differences in either the umbilical
artery pulsatility index or resistance index (Fig. 3H and
I), the middle cerebral artery pulsatility index, or the
cerebroplacental ratio between any of the groups (data
not shown). Placental pulsatility index (PPI), a measure
of placental impedance and a tool to predict fetal growth
restriction, was increased in the pregnancies of obese
untreated and obese metformin-treated dams (Fig. 3J).
The PPIwas significantly correlatedwith fetal bodyweight
(Fig. 3K).
Placentas from obese untreated and obese
metformin-treated dams have reduced labyrinthine
area and increased calcification
Male and female placentas from obese untreated but not
obese metformin-treated dams were heavier compared
to control placentas (P= 0.007, Fig. 4A). The fetal
bodyweight to placental weight ratio was reduced in both
obese untreated and obese metformin-treated animals
indicating reduced placental efficiency (P < 0.001,
Fig. 4B). Across all groups, placental efficiency was lower
in male compared to female fetuses (P = 0.001).
Male and female placentas from obese untreated dams
had a reduced labyrinthine area (P < 0.0001), the
main nutrient exchange zone of the murine placenta
(Fig. 4C and D). This reduction was not prevented by
metformin treatment (P = 0.002, Fig. 4D). Reduced
placental labyrinth is likely to be a contributor to the
reduced fetal growth as shown by the correlation between
the labyrinthine area of the placenta and fetal weight
(Fig. 4E). Placental calcification was observed solely in the
obese untreated and obese metformin-treated groups but
not in the control group (P < 0.001 for control vs. obese
untreated and obese metformin-treated group, Fig. 4F
and G). In areas with calcium deposits, the labyrinthine
structure was damaged (Fig. 4H).
Discussion
Exposure to a maternal high fat/high sugar diet resulted
in a pronounced obesity phenotype and the sub-
sequent development of glucose intolerance, insulin
resistance and reduced uterine artery compliance during
pregnancy. Metformin treatment in our model resulted
in improvement of maternal metabolic and vascular
parameters but did not improve placental or fetal
parameters.
Ultrasound imaging of the fetus and the uterine
artery is commonly used to assess human pregnancies
throughout gestation and a recent review highlighted
the importance and new opportunities of pregnancy
imaging in the field of developmental programming
(Morrison et al. 2021). The physiological drop in uterine
artery PI via vascular remodelling during pregnancy is
essential to enable low resistance placental blood flow
to support fetal growth. In human pregnancy, maternal
overweight/obesity is associated with an attenuation in
the physiological drop in uterine artery PI (Teulings et al.
2020) and there is increased likelihood of uterine artery PI
above the normal range (Kim et al. 2015). GDM has been
associated with impairment of endothelium-dependent
vasorelaxation (Knock et al. 1997), which has been
demonstrated in a murine GDM model with consequent
increased uterine artery resistance (Stanley et al. 2011).
We show for the first time that our mouse model of
maternal obesity recapitulates this, with increased levels
of sFlt in the obese dams and reduced uterine artery
compliance that correlates positively with maternal
fasting insulin levels. Our obesity mouse model therefore
recapitulates phenotypes of human obese pregnancies as
obesity is a well-known risk factor for the development
of preeclampsia (Roberts et al. 2011). SFlt (VEGR-1),
which is used as a biomarker for preeclampsia in
humans, can bind vascular endothelial growth factor
(VEGF) which leads to an angiogenic imbalance and
endothelial dysfunction (Sones & Davisson, 2016).
Metformin treatment in humans has previously been
shown to reduce the incidence of preeclampsia and
hypertensive disorders, potentially via increasing nitric
oxide, improving endothelial dysfunction, and reducing
sFlt secretion (Brownfoot et al. 2016; Romero et al.
2017; Soobryan et al. 2018). In our model, metformin
treatment improved uterine artery compliance and
reduced sFlt in thematernal serum, adding novel evidence
for metformin’s potential to prevent preeclampsia and
demonstrating that our model provides an important
platform to further elucidate mechanisms. Future work in
this area will complement currently planned human trials
of metformin for preeclampsia prevention (Cluver et al.
2019).
Currently metformin is used to treat GDM in many
settings; however, there are wide global variations in
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Figure 3. Fetuses from obese untreated and obese metformin-treated dams show symmetric growth
restriction
A, fetal weight was taken at E18.5 (n = 14/14 dams for male/female control, n = 13/14 dams male/female obese
and n = 13/13 dams for male/female metformin fetuses). B–F, fetal biometry was performed as shown (B) and
crown-rump length (C), biparietal diameter (D), head length (E) and abdominal transverse diameter (F) measured.
For the fetal biometry, n = 14/14 dams for male/female control, n = 12/13 dams for male/female obese and
n = 11/11 dams for male/female metformin fetuses are shown (linear mixed model analysis accounting for the
dam as a random effect). In the graphs the mean ± SD per litter and sex is shown. G, fetal liver weights were
taken at E18.5 in n = 14/14 dams for male/female control, n = 10/11 dams for female/male obese fetuses and
n = 11/11 dams, male/female metformin fetuses (mean ± SD, two-way ANOVA). H and I, the umbilical pulsatility
index (PI; H) and resistance index (I) were measured via ultrasound. Analysis shows n = 13/11 dams for male/female
control, n = 12/8 dams for male/female obese and n = 12/11 dams for male/female metformin fetuses (two-way
ANOVA (sex and maternal environment) with Tukey’s multiple comparison test). J, the placental pulsatility index
(PPI) was calculated via the following formula: mean uterine artery PI + mean umbilical artery PI)/2, for n = 12/10
dams for male/female control, n = 11/7 dams for male/female obese and n = 10/9 dams for male/female metformin
fetuses (two-way ANOVA). K, the PPI was correlated with the fetal body weight (linear correlation and Pearson
correlation coefficient r).
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clinical recommendations (Lindsay & Loeken, 2017).
Long-term data about possible impacts of metformin
use in pregnancy on offspring adiposity are starting
to emerge, highlighting possible increased adiposity in
mid-childhood following maternal metformin treatment
(Tarry-Adkins et al. 2019). Apart from teratology analyses
that show no increased risk of fetal anomaly following
maternal metformin exposure in pregnancy (Given et al.
2018), little data exist from clinical studies regarding
the direct impact of metformin on the placenta or
fetus, including its effect on growth (Tarry-Adkins et al.
2019). The use of a mouse model allowed us to assess
the effects of metformin exposure on the placenta
and the fetus whilst controlling other factors (such as
diet, housing conditions, genetic background). Sheep
and rodent models are commonly used in the field
of developmental programming significantly reducing
the time to generate valuable data regarding safe and
efficient interventions during pregnancy (Dickinson et al.
2016). The murine pregnancy is well characterised and
Figure 4. Placentas from obese untreated and obese metformin-treated animals show pathologies that
can explain reduced efficiency
A, placentas were weighed on the day of dissection (E18.5). B, as an indicator of placental efficiency the ratio of
body to placental weight was calculated. In A and B, n = 14 dams for male and female control, n = 13/14 dams for
male/female obese and n = 13 dams for male and female metformin placentas. C, placental sections were stained
for the trophoblast cell marker Tpbpa and the endothelial cell marker CD31 via immunohistochemistry to allow
delineation of the trophoblast and labyrinthine layer of the placenta (n = 11 dams for male and female control,
n = 12/10 dams for male/female obese and n = 13/9 dams for male/female metformin placentas).D, the percentage
of labyrinth to the whole placenta was then calculated. E, fetal body weight was correlated with the labyrinthine
area of the placenta from that individual fetus; one male and one female fetus per litter were analysed (linear
correlation and Pearson correlation coefficient r). F, the placentas were additionally stained for calcification with
an Alizarin Red stain. G, the areas stained with Alizarin Red are quantified and expressed as a percentage of the
whole placenta (n = 14 dams for male and female control, n = 13/14 dams for male/female obese and n = 13/12
dams for male/female metformin placentas). H, in areas with calcium deposition the labyrinthine structure was
damaged. Mean ± SD is shown and two-way ANOVA (sex and maternal environment) is performed with a Tukey’s
multiple comparison test.
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therefore differences between the human and the murine
pregnancy are well known. The fetal period compared
to the embryonic period is much longer in humans
compared with the mouse which is born less mature. This
is apparent when looking at fat tissue development at birth
– a new-born mouse has 1%–2% of fat compared with
16% in a new-born human (Widdowson, 1950). Although
the human and the mouse both have chorioallantoic and
haemochorial placentas, there are structural differences
and the invasion of the placental trophoblast cells into the
uterus is shallower in the mouse compared to the human
(Schmidt et al. 2015). However, once the final placenta is
established the labyrinthine zone in the mouse placenta
and the chorionic villi in the human placenta are very
similar with regard to the exchange mechanism between
maternal and fetal blood (Rossant & Cross, 2001). The
mouse is therefore a useful tool for addressing important
questions in the field of developmental programming in
relation to the placenta, such as those addressed in the
current study.
In the current study, placentas fromobese dams showed
reduced placental efficiency, evidenced by increased
calcium deposits, and reduced labyrinthine area. As the
labyrinthine zone is the main exchange zone between
the maternal and fetal circulation in the murine placenta
the reduced size and the presence of calcium depositions
is likely to restrict efficient nutrient transport to the
fetus. Increased calcium depositions are associated with
placental ageing in human pregnancy and are often
observed in placentas from obese and GDM-affected
pregnancies, highlighting that our model mimics features
of human pregnancies (Salge et al. 2012). Mechanistic
insight into how reduced labyrinthine area might occur
comes from recent transcriptomic analyses from our
laboratory showing downregulation of transcripts
involved in labyrinthine development in placentas from
obese dams (De Barros Mucci et al. 2020). We observed
a strong correlation between reduced labyrinthine area,
increased placental impedance (as measured by the PPI;
Gudmundsson et al. 2017), and reduced fetal growth.
Many different factors such as suboptimal nutrition or
smoking on the maternal side or genetic factors on the
fetal side can be associated with fetal growth restriction,
but a common feature and a driving factor is reduced
uterine-placental perfusion and reduced fetal nutrition
(Nardozza et al. 2017). It is thereby striking that despite the
significant improvements in maternal metabolic health
and uterine artery compliance observed with metformin
treatment, the adverse impacts of maternal obesity on
placental development were not prevented and fetal
growth was still significantly restricted. We hypothesise
that the mechanisms driving fetal growth restriction
differ at least partially between the obese untreated and
the obese metformin-treated pregnancies. Overall, the
fetal weight and biometry data show higher variation in
the obese untreated and the obese metformin-treated
groups compared to the control group. This may reflect
differential individual responses to the obesogenic diet
and themetformin treatment. Thematernal data highlight
different degrees of obesity and glucose intolerance in
our model that could contribute to the higher variability
in these groups regarding fetal outcomes. In humans,
metformin treatment fails in 30%–50% of women with
GDM who then require additional insulin treatment
(Tarry-Adkins et al. 2020). A difference in the response to
metformin treatmentmay therefore also explain increased
variation in the metformin-treated group in our model.
We showed a strong correlation between metformin
levels in the maternal and the fetal circulation and that
circulating concentrations were equivalent. This result is
consistent with human studies that demonstrate at least
50% of maternal metformin levels in fetal circulation
(Priya & Kalra, 2018), while some studies show equal
or higher concentrations in the fetal circulation (Vanky
et al. 2005). Importantly, we demonstrate that, as well
as entering the fetal circulation, maternally administered
metformin also appeared in fetal liver and kidney, both of
which expressed high levels of known metformin trans-
porters. Metformin was also present in the amniotic
fluid, highlighting that the fetus is repeatedly exposed to
metformin by swallowing. The immediate and long-term
consequences of direct fetal tissue exposure to metformin
are unknown. Data on metformin treatment outside
of pregnancy show that metformin activates AMPK
and can inhibit complex I in mitochondria at high
concentrations. Activation of AMPK leads to reduced
mTOR signalling; this is relevant in highly mitotic tissues
such as cancer where metformin treatment can slow cell
proliferation (Pernicova &Korbonits, 2014). Additionally,
AMPK activation leads to reduced lipid synthesis and
gluconeogenesis, mediating the beneficial effects on
metabolic health in T2D patients (Rena et al. 2017).
Recent data show thatmetformin increasesGDF-15which
increases energy expenditure and reduces food intake
and thereby reduces body weight (Coll et al. 2020). It
is possible that metformin has similar actions on fetal
and placental tissues leading to altered metabolism and
growth, which could have a negative impact, especially
given the high degree of cell proliferation and division
during development (Nguyen et al. 2018). This could
therefore contribute to the observed reduction in fetal
growth despite the correction of uterine blood flow by
metformin. It has been hypothesised that metformin may
also have epigenetic effects on the fetus that could have
long-term health consequences via changes in activity
of histone modification enzymes or DNA methylation
(Bridgeman et al. 2018; Owen et al. 2021). This highlights
the complexity of metformin use in utero and the need
for further research in light of the lack of knowledge and
understanding of metformin action in fetal tissues.
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In conclusion, our study demonstrates that metformin
has beneficial effects on maternal metabolic health and,
consistent with human data, has the potential to prevent
preeclampsia. However, despite the beneficial effects on
maternal physiology, it did not prevent obesity-induced
placental ageing and fetal growth restriction. Moreover,
metformin enters the fetal circulation and highly
proliferative fetal tissues, the long-term implications
of which are currently unknown. These findings highlight
the complex balance of risk vs. benefits that must be
considered in obstetric medical treatments and provide
a well-characterised platform for further mechanistic
research on pregnancies complicated by obesity and/or
GDM and on the actions of metformin in pregnancy.
References
Alfaradhi MZ, Fernandez-Twinn DS, Martin-Gronert MS,
Musial B, Fowden A & Ozanne SE (2014). Oxidative stress
and altered lipid homeostasis in the programming of
offspring fatty liver by maternal obesity. Am J Physiol Regul
Integr Comp Physiol 307, R26–R34.
Alfaradhi MZ & Ozanne SE (2011). Developmental
programming in response to maternal overnutrition. Front
Genet 2, 27.
American Diabetes Association (2019). 14. Management
of diabetes in pregnancy: standards of medical care in
diabetes-2019. Diabetes Care 42, S165–S172.
Blackmore HL, Niu Y, Fernandez-Twinn DS, Tarry-Adkins JL,
Giussani DA & Ozanne SE (2014). Maternal diet-induced
obesity programs cardiovascular dysfunction in adult male
mouse offspring independent of current body weight. End-
ocrinology 155, 3970–3980.
Bridgeman SC, Ellison GC, Melton PE, Newsholme P &
Mamotte CDS (2018). Epigenetic effects of metformin: from
molecular mechanisms to clinical implications. Diabetes
Obes Metab 20, 1553–1562.
Brownfoot FC, Hastie R, Sc BB, Hannan NJ, Sci B, Cannon
P, Tuohey L, Parry LJ, Senadheera S, Illanes SE, Kaitu
Uhevaha J & Tong S (2016). Metformin as a prevention
and treatment for preeclampsia: effects on soluble fms-like
tyrosine kinase 1 and soluble endoglin secretion and
endothelial dysfunction. Am J Obstet Gynecol 214,
356.e1-356.e15.
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J,
Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley
GL, Vandesompele J & Wittwer CT (2009). The MIQE
guidelines: minimum information for publication of
quantitative real-time PCR experiments. Clin Chem 55,
611–622.
Cluver C, Walker SP, Mol BW, Hall D, Hiscock R, Brownfoot
FC, Kaitu’U-Lino TJ & Tong S (2019). A double blind,
randomised, placebo-controlled trial to evaluate the efficacy
of metformin to treat preterm pre-eclampsia (PI2 Trial):
Study protocol. BMJ Open 9, e025809.
Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross
JA, Cimino I, Yang M, Welsh P, Virtue S, Goldspink DA,
Miedzybrodzka EL, Konopka AR, Esponda RR, Huang
JT-J, Tung YCL, Rodriguez-Cuenca S, Tomaz RA, Harding
HP, Melvin A, Yeo GSH, Preiss D, Vidal-Puig A, Vallier
L, Nair KS, Wareham NJ, Ron D, Gribble FM, Reimann F,
Sattar N, Savage DB, Allan BB, O’Rahilly S (2020). GDF15
mediates the effects of metformin on body weight and
energy balance. Nature 578, 444–448.
De Barros Mucci D, Kusinski LC, Wilsmore P, Loche
E, Pantaleão LC, Ashmore TJ, Blackmore HL,
Fernandez-Twinn DS, Das Graças T, do Como M &
Ozanne SE (2020). Impact of maternal obesity on placental
transcriptome and morphology associated with fetal growth
restriction in mice. Int J Obes 44, 1087–1096.
Deeney S, Powers KN & Crombleholme TM (2016). A
comparison of sexing methods in fetal mice. Lab Anim 45,
380–384.
Desoye G & Wells JCK (2021). Pregnancies in diabetes and
obesity: the capacity-load model of placental adaptation.
Diabetes 70, 823–830.
Dickinson H, Moss TJ, Gatford KL, Moritz KM, Akison
L, Fullston T, Hryciw DH, Maloney CA, Morris MJ,
Wooldridge AL, Schjenken JE, Robertson SA, Waddell
BJ, Mark PJ, Wyrwoll CS, Ellery SJ, Thornburg KL,
Muhlhausler BS & Morrison JL (2016). A review of
fundamental principles for animal models of DOHaD
research: An Australian perspective. J Dev Orig Health Dis
7, 449–472.
Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E,
Ryan EA, Fantus IG, Hutton E, Armson AB, Lipscombe
LL, Simmons D, Barrett JFR, Karanicolas PJ, Tobin S,
McIntyre HD, Tian SY, Tomlinson G, Murphy KE & MiTy
Collaborative Group (2020). Metformin in women with
type 2 diabetes in pregnancy (MiTy): a multicentre, inter-
national, randomised, placebo-controlled trial. Lancet
Diabetes Endocrinol 8, 834–844.
Fernandez-Twinn DS, Blackmore HL, Siggens L, Giussani DA,
Cross CM, Foo R & Ozanne SE (2012). The programming
of cardiac hypertrophy in the offspring by maternal obesity
is associated with hyperinsulinemia, AKT, ERK, and mTOR
activation. Endocrinology 153, 5961–5971.
Gaillard R (2015). Maternal obesity during pregnancy and
cardiovascular development and disease in the offspring.
Eur J Epidemiol 30, 1141–1152.
Given JE, Loane M, Garne E, Addor M-C, Bakker M,
Bertaut-Nativel B, Gatt M, Klungsoyr K, Lelong N, Morgan
M, Neville AJ, Pierini A, Rissmann A & Dolk H (2018).
Metformin exposure in first trimester of pregnancy and
risk of all or specific congenital anomalies: exploratory
case-control study. BMJ 361, k2477.
Gray SG, McGuire TM, Cohen N & Little PJ (2017). The
emerging role of metformin in gestational diabetes mellitus.
Diabetes Obes Metab 19, 765–772.
Grundy D (2015). Principles and standards for reporting
animal experiments in The Journal of Physiology and
Experimental Physiology. J Physiol 593, 2547–2549.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 0.0 A murine model of obesity, diabetes and metformin during pregnancy 15
Gudmundsson S, Flo K, Ghosh G, Wilsgaard T & Acharya G
(2017). Placental pulsatility index: a new, more sensitive
parameter for predicting adverse outcome in pregnancies
suspected of fetal growth restriction. Acta Obstet Gynecol
Scand 96, 216–222.
Guro L, Hanem E, Stridsklev S, Júlíusson PB, Salvesen Ø,
Roelants M, Carlsen SM, Ødegård R, Vanky E, Hanem LG
& Phd ØS (2018). Metformin use in PCOS pregnancies
increases the risk of offspring overweight at 4 years of
age; follow-up of two RCTs. J Clin Endocrinol Metab 103,
1612–1621.
Hayes EK, Lechowicz A, Petrik JJ, Storozhuk Y, Paez-Parent S,
Dai Q, Samjoo IA, Mansell M, Gruslin A, Holloway AC
& Raha S (2012). Adverse fetal and neonatal outcomes
associated with a life-long high fat diet: role of altered
development of the placental vasculature. PLoS One 7,
e33370.
Hernandez-Andrade E, Ahn H, Szalai G, Korzeniewski
SJ, Wang B, King M, Chaiworapongsa T, Than NG &
Romero R (2014). Evaluation of utero-placental and fetal
hemodynamic parameters throughout gestation in pregnant
mice using high-frequency ultrasound. Ultrasound Med Biol
40, 351–360.
Hill B, Skouteris H, Teede HJ, Bailey C, Baxter J-AB,
Bergmeier HJ, Borges ALV, Harrison CL, Jack B, Jorgensen
L, Lim S, Montanaro C, Redman L, Steegers E, Stephenson
J, Sundseth H, Thangaratinam S, Walker R & Boyle JA
(2019). Health in preconception, pregnancy and post-
partum global alliance: international network preconception
research priorities for the prevention of maternal obesity
and related pregnancy and long-term complications. J Clin
Med 8, 2119.
Holmgren M, Wåhlin A, Dunås T, Malm J & Eklund A
(2020). Assessment of cerebral blood flow pulsatility and
cerebral arterial compliance with 4D flow MRI. J Magn
Reson Imaging 51, 1516–1525.
Hu Z, Tylavsky FA, Han JC, Kocak M, Fowke JH, Davis RL,
Lewinn K, Bush NR & Zhao Q (2019). Maternal metabolic
factors during pregnancy predict early childhood growth
trajectories and obesity risk: the CANDLE Study. Int J Obes
43, 1914–1922.
Isganaitis E, Woo M, Ma H, Chen M, Kong W, Lytras
A, Sales V, DeCoste-Lopez J, Lee KJ, Leatherwood C,
Lee D, Fitzpatrick C, Gall W, Watkins S & Patti ME
(2014). Developmental programming by maternal insulin
resistance: Hyperinsulinemia, glucose intolerance, and
dysregulated lipid metabolism in male offspring of
insulin-resistant mice. Diabetes 63, 688–700.
Janssen BJA, De Celle T, Debets JJM, Brouns AE, Callahan
MF & Smith TL (2004). Effects of anesthetics on systemic
hemodynamics in mice. Am J Physiol Heart Circ Physiol
287, H1618–H1624.
Jarvie E, Hauguel-de-Mouzon S, Nelson SM, Sattar N,
Catalano PM & Freeman DJ (2010). Lipotoxicity in obese
pregnancy and its potential role in adverse pregnancy
outcome and obesity in the offspring. Clin Sci (Lond) 119,
123–129.
Jenkins B, Ronis M & Koulman A (2020). Lc–ms lipidomics:
Exploiting a simple high-throughput method for the
comprehensive extraction of lipids in a ruminant fat
dose-response study. Metabolites 10, 1–27.
Kim YH, Lee HJ, Shin JE, Lee Y, Shin JC, Park TC & Park IY
(2015). The predictive value of the uterine artery pulsatility
index during the early third trimester for the occurrence of
adverse pregnancy outcomes depending on the maternal
obesity. Obes Res Clin Pract 9, 374–381.
Knock GA, McCarthy AL, Lowy C & Poston L (1997).
Association of gestational diabetes with abnormal maternal
vascular endothelial function. BJOG An Int J Obstet
Gynaecol 104, 229–234.
Lahti-Pulkkinen M, Bhattacharya S, Wild SH, Lindsay RS,
Räikkönen K, Norman JE, Bhattacharya S & Reynolds RM
(2019). Consequences of being overweight or obese during
pregnancy on diabetes in the offspring: a record linkage
study in Aberdeen, Scotland. Diabetologia 62, 1412–1419.
Liao MZ, Flood Nichols SK, Ahmed M, Clark S, Hankins
GD, Caritis S, Venkataramanan R, Haas D, Quinney SK,
Haneline LS, Tita AT, Manuck T, Wang J, Thummel KE,
Brown LM, Ren Z, Easterling TR & Hebert MF (2020).
Effects of pregnancy on the pharmacokinetics of metformin.
Drug Metab Dispos 48, 264–271.
Lindsay RS & Loeken MR (2017). Metformin use in
pregnancy: promises and uncertainties. Diabetologia 60,
1612–1619.
Maragkoudaki X, Naylor M, Papacleovoulou G, Stolarczyk E,
Rees D, Pombo JM, Abu-Hayyeh S, Czajka A, Howard JK,
Malik AN, Williamson C, Poston L & Taylor PD (2020).
Supplementation with a prebiotic (polydextrose) in obese
mouse pregnancy improves maternal glucose homeo-
stasis and protects against offspring obesity. Int J Obes 44,
2382–2393.
McFarlane L, Truong V, Palmer JS, Wilhelm D, Schmid M &
Wilhelm D (2013). E-mail novel PCR assay for determining
the genetic sex of mice. Sex Dev 7, 207-211.
McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER
& Damm P (2019). Gestational diabetes mellitus. Nat Rev
Prim 5, 47 .
Mitanchez D, Yzydorczyk C, Siddeek B, Boubred F, Benahmed
M & Simeoni U (2015). The offspring of the diabetic
mother – short-and long-term implications. Best Pract Res
Clin Obstet Gynaecol 29, 256–269.
Morrison JL, Ayonrinde OT, Care AS, Clarke GD, Darby JRT,
David AL, Dean JM, Hooper SB, Kitchen MJ, MacGowan
CK, Melbourne A, McGillick EV, McKenzie CA, Michael
N, Mohammed N, Sadananthan SA, Schrauben E, Regnault
TRH & Velan SS (2021). Seeing the fetus from a DOHaD
perspective: discussion paper from the advanced imaging
techniques of DOHaD applications workshop held at the
2019 DOHaD World Congress. J Dev Orig Health Dis 12,
153–167.
Nardozza LMM, Caetano ACR, Zamarian ACP, Mazzola
JB, Silva CP, Marçal VMG, Lobo TF, Peixoto AB &
Araujo Júnior E (2017). Fetal growth restriction: current
knowledge. Arch Gynecol Obstet 295, 1061–1077.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
16 A. Hufnagel and others J Physiol 0.0
Nguyen L, Chan S-Y, Kee A & Teo K (2018). Metformin from
mother to unborn child - are there unwarranted effects?
EBioMedicine 35, 394–404.
NICE (The National Institute for Health and Care Excellence)
(2015). Diabetes in pregnancy: management from pre-
conception to the postnatal period. Available at: https:
//www.nice.org.uk/guidance/ng3 [Accessed April 30, 2020].
Ochi H, Kusanagi Y, Katayama T, Matsubara K & Ito M
(2003). Clinical significance of normalization of uterine
artery pulsatility index with maternal heart rate for the
evaluation of uterine circulation in pregnancy-induced
hypertension. Ultrasound Obstet Gynecol 21,
459–463.
Orchard GE (2013). Pigments and minerals. In Bancroft’s
Theory and Practice of Histological Techniques, pp. 239–270.
Elsevier.
Owen MD, Baker BC, Scott EM & Forbes K (2021). Inter-
action between metformin, folate and vitamin B 12 and
the potential impact on fetal growth and long-term
metabolic health in diabetic pregnancies. Int J Mol Sci 22,
5759.
Pantham P, Aye I & Powell TL (2015). Inflammation in
maternal obesity and gestational diabetes mellitus. Placenta
36, 709–715.
Pernicova I & Korbonits M (2014). Metformin-mode of action
and clinical implications for diabetes and cancer. Nat Publ
Gr 10, 143–156.
Priya G & Kalra S (2018). Metformin in the management of
diabetes during pregnancy and lactation. Drugs Context 7,
212523.
Rena G, Hardie DG & Pearson ER (2017). The mechanisms of
action of metformin. Diabetologia 60, 1577–1585.
Roberts JM, Bodnar LM, Patrick TE & Powers RW (2011).
The role of obesity in preeclampsia. Pregnancy Hypertens 1,
6–16.
Romero R, Hüttemann M, Maymon E, Panaitescu B,
Conde-Agudelo A, Pacora P, Yoon BH & Grossman LI
(2017). Metformin, the aspirin of the 21 st century: its
role in gestational diabetes, prevention of preeclampsia and
cancer, and the promotion of longevity HHS Public Access.
Am J Obs Gynecol 217, 282–302.
Rossant J & Cross JC (2001). Placental development: lessons
from mouse mutants. Nat Rev Genet 2, 538–548.
Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T &
Hague WM (2011). Metformin in gestational diabetes: the
offspring follow-up (MiG TOFU): body composition at 2
years of age. Diabetes Care 34, 2279–2284.
Salge AKM, Rocha KMN, Xavier RM, Ramalho WS,
Rocha ÉL, Guimarães JV, Silva R, Siqueira KM, Abdalla
DR, Michelin MA & Murta EFC (2012). Macroscopic
placental changes associated with fetal and maternal
events in diabetes mellitus. Clinics (Sao Paulo) 67,
1203–1208.
Salomäki H, Vä Hä Talo LH, Laurila K, Jä Ppinen NT,
Penttinen A-M, Ailanen L, Ilyasizadeh J, Pesonen U,
Koulu M & Aguila MB (2013). Prenatal metformin
exposure in mice programs the metabolic phenotype of the
offspring during a high fat diet at adulthood. PLoS One 8,
e56594.
Samuelsson AM, Matthews PA, Argenton M, Christie MR,
McConnell JM, Jansen E, Piersma AH, Ozanne SE, Twinn
DF, Remacle C, Rowlerson A, Poston L & Taylor PD (2008).
Diet-induced obesity in female mice leads to offspring
hyperphagia, adiposity, hypertension, and insulin resistance:
a novel murine model of developmental programming.
Hypertension 51, 383–392.
Schäfer-Graf UM, Gembruch U, Kainer F, Groten T,
Hummel S, Hösli I, Grieshop M, Kaltheuner M, Bührer
C, Kautzky-Willer A, Laubner K & Bancher-Todesca D
(2018). Gestational diabetes mellitus (GDM), diagnosis,
treatment and follow-up. Guideline of the DDG and DGGG
(S3 Level, AWMF Registry Number 057/088, February
2018). Geburtshilfe Frauenheilkd 78, 1219–1231.
Schmidt A, Morales-Prieto DM, Pastuschek J, Fröhlich K &
Markert UR (2015). Only humans have human placentas:
molecular differences between mice and humans. J Reprod
Immunol 108, 65–71.
Society of Endocrinology and Metabolism of Turkey (2019).
Clinical Practice Guideline for Diagnosis, Treatment and
Follow-up of Diabetes Mellitus and Its Complications, 2019.
Pp. 268. Available at: https://temd.org.tr/admin/uploads/
tbl_kilavuz/20191107144832-2019tbl_kilavuz7c65cb4e70.
pdf [Accessed March 3, 2021].
Society for Maternal-Fetal Medicine (2018). SMFM Statement:
pharmacological treatment of gestational diabetes. Am J
Obstet Gynecol 218, B2–B4.
Sones JL & Davisson RL (2016). Preeclampsia, of mice and
women. Physiol Genomics 48, 565–572.
Soobryan N, Murugesan S, Pandiyan A, Moodley J & Mackraj
I (2018). Angiogenic dysregulation in pregnancy-related
hypertension—a role for metformin. Reprod Sci 25,
1531–1539.
Stanley JL, Cheung CC, Sankaralingam S, Baker PN &
Davidge ST (2011). Effect of gestational diabetes on
maternal artery function. Reprod Sci 18, 342–352.
Steculorum SM & Bouret SG (2011). Maternal diabetes
compromises the organization of hypothalamic feeding
circuits and impairs leptin sensitivity in offspring. End-
ocrinology 152, 4171–4179.
Stephenson J, Heslehurst N, Hall J, Schoenaker D, Hutchinson
J, Cade JE, Poston L, Barrett G, Crozier SR, Barker M,
Kumaran K, Yajnik CS, Baird J & Mishra GD (2018). Pre-
conception health 1 Before the beginning: nutrition and
lifestyle in the preconception period and its importance for
future health. Lancet 391, 1830–1841.
Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R,
Kotecha R, Pastides A & Shehata H (2016). Metformin
versus placebo in obese pregnant women without diabetes
mellitus. N Engl J Med 374, 434–443.
Tarry-Adkins JL, Aiken CE & Ozanne SE (2019). Neonatal,
infant, and childhood growth following metformin versus
insulin treatment for gestational diabetes: a systematic
review and meta-analysis. PLoS Med 16, e1002848.
Tarry-Adkins JL, Aiken CE & Ozanne SE (2020). Comparative
impact of pharmacological treatments for gestational
diabetes on neonatal anthropometry independent of
maternal glycaemic control: a systematic review and
meta-analysis. PLoS Med 17, e1003126.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 0.0 A murine model of obesity, diabetes and metformin during pregnancy 17
Teulings N, Wood AM, Sovio U, Ozanne SE, Smith GCS
& Aiken CE (2020). Independent influences of maternal
obesity and fetal sex on maternal cardiovascular adaptation
to pregnancy: a prospective cohort study. Int J Obes 44,
2246–2255.
Vanky E, Zahlsen K, Spigset O & Carlsen SM (2005). Placental
passage of metformin in women with polycystic ovary
syndrome. Fertil Steril 83, 1575–1578.
Widdowson BEM (1950). Chemical composition of newly
born mammals. Nature 166, 626–628.
Zhang J & Croy A (2009). Using ultrasonography to define
fetal-maternal relationships: Moving from humans to mice.
Comp Med 59, 527–553.
Additional information
Data availability statement
All analysed data can be found in the manuscript, raw datasets
are available upon request.
Competing interests
The authors declare that they have no competing interests.
Author contributions
A.H., D.S.F. and S.E.O. designed research; A.H., D.S.F., H.L.B.,
T.A. performed research; B.J. and A.K. performed LC-MS
analysis; R.A.H. and I.P.H. provided intellectual input; A.H.
analysed data andwrote the paper with input fromD.S.F., C.E.A.
and S.E.O. All authors read, commented on, and approved
the final version of the manuscript. All persons designated as
authors qualify for authorship, and all those who qualify for
authorship are listed.
Funding
This work was supported by the BHF (PG/13/46/30329)
and the MRC (MC_UU_00014/4). C.E.A. is supported
by a Medical Research Council New Investigator Grant
(MR/T016701/1). A.H. was supported by a Wellcome
Trust studentship (108926/B/15/Z). S.E.O. is a member
of the Cambridge BHF Centre of Research Excellence
(RE/18/1/34212). S.E.O. and D.S.F.T. are supported by the
Medical Research Council (MC_UU_12012/4) and the British
Heart Foundation (RG/17/12/33167). The histology core is
funded by the MRC (MC_UU_00014/5) and the imaging core
of the Institute of Metabolic Science by a Wellcome Major
Award(208363/Z/17/Z). This research was funded in part by
the Wellcome Trust [108926/B/15/Z]. For the purpose of open
access, the author has applied a CC BY public copyright licence
to any Author Accepted Manuscript version arising from this
submission.
Acknowledgements
The authors thank C. Custance (University of Cambridge
Metabolic Research Laboratories and MRC Metabolic Diseases
Unit, Wellcome Trust-MRC Institute of Metabolic Science,
Addenbrooke’s Hospital, Cambridge, UK) for expert technical
assistance. The authors thank the histology core (J. Warner,
MRC Metabolic Diseases Unit) and B. Mahler-Araujo
(Histopathology Addenbrookes) for their expert histology
advice. We would also like to acknowledge the imaging
core of the Institute of Metabolic Science (G. Strachan) and
the Metabolomics and Lipidomics Laboratory core (NIHR
Cambridge Biomedical Research Centre). The authors also
thank Dr N. Shreeve and Dr C. Murdoch for their help in
setting up murine uterine and fetal ultrasound.
Keywords
developmental programming, gestational diabetes mellitus,
maternal obesity, metformin, placenta
Supporting information
Additional supporting information can be found online in the
Supporting Information section at the end of the HTML view of
the article. Supporting information files available:
Peer Review History
Stastical Summary Document
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
